Skip to content
Boca Raton City Online – Lifestyle
Author:
Crystalys Therapeutics / Russo Partners
Crystalys Therapeutics Announces $130 Million Series B Financing to Advance Global Phase 3 Development and Commercialization of Dotinurad for Gout
July 22, 2026
Crystalys Therapeutics Doses First Patients in New Phase 2 Trial of Dotinurad for Difficult-to-Treat Gout
May 26, 2026
Crystalys Therapeutics Appoints Tim Walbert, Former Horizon Therapeutics CEO, as Independent Board Director
March 6, 2026